Lafora Disease is a rare, inherited brain disorder. It causes seizures and muscle jerks, often starting in the teens or early twenties. The disease gets worse over time, leading to problems with thinking, movement, and coordination. Sadly, most people with Lafora Disease don't live past age 25.
Every report comes from a Lived member, sent anonymously.
Have you tried Valproic Acid for Lafora Disease?
Lafora disease is a rare inherited brain disorder that causes epilepsy that worsens over time, together with a gradual loss of thinking, memory and coordination. It belongs to a small group of conditions called progressive myoclonus epilepsies, in which seizures are combined with myoclonus: sudden, involuntary jerks of a muscle group or the whole body. In Lafora disease these jerks often happen at rest and can be set off by movement, excitement or flashing light. Symptoms usually begin in late childhood or the teenage years, most often around age 13, in someone who had been developing normally. The first sign is often a convulsive seizure (a generalized tonic-clonic seizure, with stiffening, jerking and loss of consciousness) or a seizure that affects vision, causing brief blindness or visual hallucinations. Changes in mood, behavior, concentration and speech often appear around the same time. Over several years seizures become harder to control, and dementia, unsteady movement and swallowing problems develop. The disease is very rare, affecting roughly four people in every million.
Lafora disease is genetic. It is caused by changes (variants) in both copies of one of two genes, EPM2A or NHLRC1 (also called EPM2B). These genes make two proteins, laforin and malin, that work together to keep glycogen, the body's stored form of sugar, in a normal shape. When either protein is missing, an abnormal form of glycogen that cannot be broken down collects into clumps called Lafora bodies. These form in many tissues, but nerve cells in the brain are especially vulnerable, and their gradual loss produces the symptoms. These two genes explain most cases; in a small share, the genetic cause has not yet been found. The condition is inherited in an autosomal recessive pattern: a child is affected only after receiving a nonworking copy of the gene from each parent. Parents who each carry one copy are usually healthy, so there is often no known family history. Lafora disease occurs worldwide but is more common in Mediterranean countries, North Africa, the Middle East, parts of Central and South Asia, and communities where marriage between relatives is more common. Flashing lights, excitement and movement can worsen the jerks once the disease is present, but nothing a person or their parents did causes it.
Lafora disease is often recognized late. In its early stage it can look like juvenile myoclonic epilepsy (JME), a much more common teenage epilepsy that usually responds well to medicine. Features that should prompt a neurologist to consider a progressive myoclonus epilepsy instead include seizures that keep returning despite treatment, jerks that occur at rest, seizures that affect vision, and new problems with thinking, school performance or behavior. An electroencephalogram (EEG), a recording of the brain's electrical activity through sensors on the scalp, is a key test. In Lafora disease it often shows slowing of the normal background rhythm along with bursts of epileptic activity, frequently strongest over the back of the head, the region that handles vision. EEG changes can appear even when symptoms are still mild. Genetic testing that finds disease-causing variants in both copies of EPM2A or NHLRC1 confirms the diagnosis and is now the standard. A skin biopsy, in which a small sample of skin is examined under a microscope for Lafora bodies, was once the main test, but it can give both false positive and false negative results. A confirmed genetic diagnosis also lets the family receive genetic counseling about what it means for parents and siblings.
There is currently no treatment that stops or reverses Lafora disease. Care aims to reduce seizures and jerks, preserve abilities for as long as possible, and keep the person comfortable and safe. Anti-seizure medicines are the core of treatment. Seizures often respond partly at first, then become drug-resistant, and many people eventually take a combination of three or four medicines. Specialists favor a limited number of medicines that also calm myoclonus, chosen for tolerability. Newer anti-seizure medicines tend to cause fewer side effects, but none has been shown to change the overall course. Perampanel (Fycompa), an anti-seizure medicine, has been reported to help some people with Lafora disease more than other options, though this comes from small case reports rather than controlled trials. Metformin, a common diabetes medicine, has been studied because it slowed the disease in mice, and the European Medicines Agency designated it as an orphan medicine for Lafora disease. In a small group of 12 people treated at middle or late stages, it was generally safe, but only three improved, and two of them only temporarily. Some specialists suggest trying it as early as possible; whether it slows the disease in people is not known. Stomach upset can limit the dose. As symptoms advance, physical, cognitive and swallowing therapy help maintain function and prevent complications. A feeding tube placed into the stomach (a gastrostomy) may become necessary when swallowing is no longer safe. Research is active: an experimental medicine called ION283, designed to reduce the production of glycogen in the brain, has entered a first safety study in people, and gene therapies are being tested in animals. An experimental enzyme treatment did not help in a small group of patients. None of these research treatments is yet available or proven, but asking about clinical trials is reasonable.
Lafora disease progresses, but the pace varies from person to person. In a review of about 300 genetically confirmed cases, half of people had lost the ability to manage daily life independently within about 6 years of their first symptoms, and half were still alive 11 years after onset, with some living considerably longer. The specific gene change may influence the pace, but it cannot predict an individual's course with certainty. In the first years, seizures, jerks and difficulty concentrating can disrupt school, work and independence. Over time, the jerks become more frequent and interfere with walking, eating and handwriting, memory and judgment decline, and speech becomes harder to understand. In the later stage, people need full-time care. Seizure clusters become common, and complications such as aspiration pneumonia (a lung infection caused by food or saliva entering the airway), breathing failure, stiffness and pressure sores become major concerns. Prolonged seizures and breathing complications are the most common causes of death. Care works best when it is coordinated by an epilepsy center, with neurology, rehabilitation, nutrition and nursing support. Many families care for the person at home with a specialist team, reserving hospital stays for emergencies that cannot be handled there. The demands on parents and other caregivers are heavy, and practical, emotional and professional support for them is part of good care.
See a neurologist, ideally at an epilepsy center, if a teenager or young adult with epilepsy has seizures that keep returning despite treatment, develops jerks at rest or seizures that affect vision, or shows a decline in thinking, school performance or behavior. These signs warrant testing for a progressive myoclonus epilepsy even if juvenile myoclonic epilepsy has already been diagnosed. For someone already diagnosed, contact the care team promptly if seizures or jerks are becoming more frequent, or if coughing or choking during meals or a new fever or cough appears, since swallowing problems can lead to pneumonia. Call 911 if a seizure lasts more than 5 minutes, if one seizure follows another before the person recovers, or if the person does not wake up or return to their usual state afterward. Prolonged seizures (status epilepticus) are a leading cause of death in Lafora disease, and treatment works best when given early.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Lafora Disease is like, what's helped you, or ask the community a question.